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ments. However, these drugs show slow onset of action and limited 
efficacy, making necessary the use of drug augmentation strategies 
or more aggressive interventions. Two important observations have 
emerged in recent years indicating that more rapid and effective 
antidepressant treatments are possible. On the one hand, the deep 
brain stimulation (DBS) of ventral anterior (subgenual) cingulate 
cortex (Cg25) evokes rapid mood improvements in subgroups of 
treatment-resistant depressive patients, likely mediated by a func-
tional remodeling of cortico-limbic circuits. On the other hand, the 
noncompetitive NDMA receptor antagonist ketamine can also evoke 
raid (eg, 2 hours) and persistent (up to 1 week) improvements in some 
treatment-resistant patients. Moreover, recent preclinical observa-
tions indicate the antidepressant capacity of nGluR agents. Overall, 
this supports the usefulness of glutamatergic transmission as a new 
area in antidepressant drug development. On the monoamine side, 
new preclinical and clinical research should clarify the different roles 
played by 5-HT receptors in depression as well as the brain areas and 
circuits responsible for therapeutic improvement. This will lead to the 
synthesis of new agents blocking the serotonin (and possibly norepi-
nephrine) transporter, which will also activate or block 5-HT recep-
tors playing, respectively, positive (eg, postsynaptic 5-HT1A, 5-HT4) 
or negative (eg, presynaptic 5-HT1A,/1B, 5-HT2A, 5-HT2C,5-HT3) 
roles in antidepressant effects.
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Summary: Intravenous fat emulsion (IFE) has been used as an 
antidote and is most extensively studied for the treatment of local 
anesthetic toxicity. New applications beyond local anesthetic are pro-
posed, including calcium channel blockers, cyclic antidepressants, 
clomipramine, and β -adrenergic antagonists. There are 3 proposed 
mechanisms of action of IFE in toxicology: modulation of intra-
cellular metabolism, a lipid sink or sponge mechanism, and activa-
tion of ion channels. The lipid sink/sponge model is the most likely 
mechanism. Several experimental models demonstrate the benefit of 
IFE in bupivacaine, calcium channel blockers, cyclic antidepressants, 
and β -adrenergic antagonist toxicity. Multiple case reports using IFE 
in a variety of drug toxicity report improvement. Potential adverse 
effects may limit use but have been reported infrequently, and the 
benefit of IFE may outweigh potential risks. The dose, timing of 
administration, and the uses and comparison with other treatments 
are in need of future studies. The recommended dose of 20% IFE is a 
1.5-mL/kg bolus followed by 0.25 mL/kg/min or 15 mL/kg/h to run 
for 30 to 60 minutes. The bolus can be repeated several times for 
persistent asystole, and the infusion rate can be increased if blood 
pressure decreases.
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Summary: Paracetamol poisoning was first reported > 45 years ago, 
but its optimum management is still a matter of debate. In part this 
is because of the difficulty in precise risk stratification early in poi-
soning and a lack of effective antidotal treatments for those who 
present late after ingestion. National drug regulatory and poisons 
information systems in different countries provide different advice, 
and the United Kingdom changed its risk stratification advice in 2012 
after > 30 years. Observational data suggest that repeated ingestions 
of lower doses may cause more severe liver damage than a single 
ingestion, but the reasons for this remain unclear. The antidote IV 
acetylcysteine is given in a complex dose regimen that is not tailored 
to the amount of toxin ingested, and the initial duration of antidote 
therapy was determined empirically in the mid-1970s. Adverse effects 
to the antidote acetylcysteine are a further challenge, as they are more 
frequent at lower paracetamol concentrations.
We have recently been able to establish a population estimate of 
risk, which shows that early presentation managed conventionally 
results in good outcome and that mortality is almost always in those 
presenting > 15 hours after first ingestion. Co-ingestion of other drugs 
that delay gastric motility and the introduction of modified-release 
paracetamol products further complicate management approaches, 
and the safety of marketing of SR preparations must be questioned 
from a public health perspective. New biomarkers offer the potential 
to better identify patients who are at specific risk, and appear to pre-
cede, and better predict, than rises in the traditional transaminases. 
Newer, modified acetylcysteine regimens should improve its safety 
profile. Linked to new biomarkers, these potentially offer shorter 
durations of hospital stay for paracetamol overdose.
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Summary: Progress in the treatment of inborn errors of metabolism 
has derived from insight into their causes and has focused on nutri-
tional limitation of a substrate or replacement of missing products, 
the removal of toxic metabolites and maximizing anabolism, or com-
pensatory expression of a protein whose deficiency causes disease 
through stem cell or organ transplantation.
The knowledge of the biochemistry and the pathway of lysosomal 
enzymes and the concept of systemic delivery of a deficient enzyme 
carrying a mannose-6-phosphate residue that serves as recognition 
marker for both uptake and transport to lysosomes resulted in the 
first successful enzyme replacement therapies in patients with lyso-
somal storage disorders.
The use of small molecules as therapeutic agents is another 
approach that is being applied widely to inborn errors of metabolism. 
This is illustrated by substrate reduction therapy, which has shown 
to be effective in some lysosomal storage disorders and complements 
some of the limitations of enzyme-replacement therapy (eg, crossing 
the blood-brain barrier). Pharmacologic chaperones generally bind 
directly to mutant proteins and mediate improvement in the folding, 
the transport, or the stability and hence elevated levels of mutant 
protein with residual function. One example for this is treatment 
with pharmacologic doses of cofactor or cofactor analogues such as 
in phenylketonuria. Other novel therapeutic approaches include the 
use of “old” approved drugs to compensate for functional deficits or 
antagonize unwanted effects. One example is the use of losartan to 
reduce TGF-b activity in Marfan’s syndrome and other genetically 
caused forms of aortic aneurysm.
Finally, new developments will be discussed such as manipulation 
of gene expression by suppression of nonsense-mediated decay or 
manipulation of pre-mRNA splicing using short oligonucleotides. 
